Oncology

In part 2 of our video interview, Doug Hackenyos, oncology pharmacy clinical coordinator at the University of Connecticut, discusses the effects of COVID-19 on cancer care pharmacy.

Officials with the FDA have granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy, Immunomedics Inc.) for previously-treated adult patients with metastatic triple-negative breast cancer.

"With the introduction of this ibrutinib-rituximab combination, patients now have a more effective, non-chemoimmunotherapy option."

In a video interview with Drug Topics®, Doug Hackenyos, oncology pharmacy clinical coordinator at the University of Connecticut, discusses the effects of COVID-19 on cancer care pharmacy. 

Officials with the FDA today approved tucatinib (Tukysa, Seattle Genetics) in combination with chemotherapy trastuzumab and capecitabine for the treatment of adults with advanced forms of HER2-positive breast cancer.

A recent meta-analysis showed an association between regular aspirin use and reduced risk of developing several cancers of the digestive tract.

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

In part 2 of our video interview, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed drug shortages, FDA emergency use authorizations, and the biggest concerns for pharmacists.

In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.

Officials with the FDA have approved durvalumab (Imfinzi) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), in combination with standard-of-care (SoC) chemotherapies, in adult patients.

After a steady climb, a new study showed that death rates for melanoma in the United States have dropped over the last few years.

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

Special consideration for pain management in patients with cancer. 

OptumRx’s most recent pipeline outlook for 2020 reveals key therapeutic areas in the lineup.

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

FDA approval decision expected in the second quarter of 2020.

Proton pump inhibitors (PPIs) may be linked to concentration and memory problems in individuals with a history of breast cancer.

Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.

Olaparib (Lynparza, Merck and AstraZeneca) is approved for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic cancer.

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo and AstraZeneca) is a new treatment option for patients with HER2-positive breast cancer who have progressed after 2 or more prior regimens.

Approximately 1 in 8 women living in the United States will develop an invasive form of breast cancer at some point in her life

Various factors can affect a patient’s survival rate.

Monoclonal antibody originally approved in 2016.

Recent approval under new international Project Orbis.